



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/00	A2	(11) International Publication Number: WO 99/63977 (43) International Publication Date: 16 December 1999 (16.12.99)
(21) International Application Number: PCT/JP99/03057 (22) International Filing Date: 8 June 1999 (08.06.99) (30) Priority Data: 10/160270 9 June 1998 (09.06.98) JP (71) Applicant (for all designated States except US): TAKEDA CHEMICAL INDUSTRIES, LTD. [JP/JP]; 1-1, Doshomashi 4-chome, Chuo-ku, Osaka-shi, Osaka 541-0045 (JP). (72) Inventors; and (75) Inventors/Applicants (for US only): OHKAWA, Shigenori [JP/JP]; 45-20, Makamicho 6-chome, Takatsuki-shi, Osaka 569-1121 (JP). MIYAMOTO, Masaomi [JP/JP]; 12-11, Gotenyama 4-chome, Takarazuka-shi, Hyogo 665-0841 (JP). (74) Agents: ASAHINA, Tadao et al.; Osaka Plant of Takeda Chemical Industries, Ltd., 17-85, Jusohonmachi 2-chome, Yodogawa-ku, Osaka-shi, Osaka 532-0024 (JP).		(81) Designated States: AE, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING SLEEP DISORDERS (57) Abstract The present invention provides a pharmaceutical composition for treating or preventing sleep disorders which comprises (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide in combination with at least one active component selected from zolpidem, zopiclone, triazolam and brotizolam.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

Description

Pharmaceutical Composition for Treating or Preventing Sleep Disorders

5 Technical field

The present invention relates to a pharmaceutical composition for treating or preventing sleep disorders which comprises (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide in
10 combination with at least one active component selected from zolpidem, zopiclone, triazolam and brotizolam.

Background art

Sleep disorders can be classified into about 90
15 different types based on features of symptoms, cause of disease, etc. (International Classification of Sleep Disorders (ICSD): In diagnostic and Coding Manual; American Sleep Disorder Association; Allen Press Inc.: Lawrence, Kansas, 1990). Most of medicines for treating these
20 disorders at present are benzodiazepines and their derivatives. Non-benzodiazepines such as zolpidem, zopiclone, etc., which are comparatively new hypnotics, are structurally different from benzodiazepines, but exhibit the same activities as benzodiazepines through
25 benzodiazepine receptors. It is believed that benzodiazepines lower the activity of information proceeding by sedating the limbic system and hypothalamus and induce sleep. Further, it is known that benzodiazepines do not increase REM (rapid eye movement)
30 sleep and increase non-REM sleep only.

On the other hand, it is disclosed in WO 97/32871 that various tricyclic compounds including (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-

yl)ethyl]propionamide, have an excellent activity as melatonin agonists and are useful for treating or preventing sleep disorders, etc.

5 Brief description of drawings

Effects of compound A and triazolam on sleep latencies at nighttime in monkeys. Each value shows the mean latency to appear each sleep stages (SEM). S1+S2: stage 1 and stage 2; S3: stage 3; S4: stage 4 and REM: rapid eye
10 movement. *P<0.05 compared with control group (paired t-test).

Disclosure of the invention

It is indicated that known hypnotics have many
15 problems such as transient insomnia (rebound insomnia) [Science, Vol.201, pages 1039-1041, 1978], dysmnnesia such as anterograde amnesia [Psychopharmacology, Vol.70, pages 231-237, 1980, Neuroscience and Biobehavior Review, Vol.9, Pages 87-94, 1985], ataxia after sleep-awake and somnolence.
20 Therefore, it is desired to develop a hypnotic without these problems.

The inventors of the present invention made intensive studies and as a result, they found that (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-
25 yl)ethyl]propionamide (hereinafter referred to as compound A) in combination with at least one active component selected from zolpidem, zopiclone, triazolam and brotizolam (as a pharmaceutical mixture, combination dosage form or concomitant pharmacotherapy) produces
30 clinically beneficial effects as a medication exhibiting remarkable efficacy in the therapy (treating) and prophylaxis (preventing) of sleep disorders with substantially no risk for side effects such as recoil

insomnia, dysmnnesia, ataxia after sleep-awake and
somnia and hence is safe than monotherapy using any of
the above-mentioned active components. The present
invention has been developed on the basis of the above
5 finding.

Namely, the present invention provides a
pharmaceutical composition for treating or preventing
sleep disorders which comprises compound A in combination
with at least one active component selected from zolpidem,
10 zopiclone, triazolam and brotizolam,

a method for reducing amounts and(or) side effects
of benzodiazepines administered to a mammal which comprises
administering to such mammal an effective amount of
melatonin agonists in combination with benzodiazepines,

15 a method for reducing amounts and(or) side effects
of benzodiazepines administered to a mammal which comprises
administering to such mammal an effective amount of
compound A in combination with benzodiazepines,

a method for reducing amounts and(or) side effects
20 of active component(s) (zolpidem, zopiclone, triazolam
and/or brotizolam) administered to a mammal for treating
or preventing sleep disorders which comprises
administering to such mammal an effective amount of
compound A in combination with at least one active component
25 selected from zolpidem, zopiclone, triazolam and
brotizolam, and

a pharmaceutical composition for treating or
preventing sleep disorders which comprises compound A in
combination with at least one active component selected
30 from non-benzodiazepines, etc.

Compound A used in the present invention can be
produced by the methods disclosed in Example 11 of WO
97/32871 or analogous methods thereto.

Zolpidem is N,N,6-trimethyl-2-(4-methylphenyl)-imidazo[1,2-a]pyridine-3-acetamide and can be produced by the methods disclosed in Japanese Patent Unexamined Publication No. 8384/1988(S63) (USP 4794185) or analogous methods thereto.

Zopiclone is 4-methyl-1-piperazinecarboxylic acid 6-(5-chloro-2-pyridinyl)-6,7-dihydro-7-oxo-5H-pyrrolo[3,4-b]pyrazin-5-yl ester and can be produced in the methods disclosed in Japanese Patent Unexamined Publication No. 76892/1973(S48) (USP 3862149) or analogous methods thereto.

Triazolam (halcion) is 8-chloro-6-(2-chlorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine and can be produced by the methods disclosed in Japanese Patent Unexamined Publication No. 76892/1973(S48) (USP 3987052) or analogous methods thereto.

Brotizolam (lendormin) is 8-bromo-6-(o-chlorophenyl)-1-methyl-4H-s-triazolo[3,4c]thieno[2,3e]1,4-diazepine and can be produced by the methods disclosed in Japanese Patent Unexamined Publication No. 80899/1976(S51) (USP 4094984) or analogous methods thereto.

The pharmaceutical composition for treating or preventing sleep disorders in the present invention comprises compound A in combination with at least one active component selected from zolpidem, zopiclone, triazolam and brotizolam as active components. This composition can be used orally in the form of a dosage form available on each of the above components or mixing each of the above components with a pharmacologically acceptable carrier or excipient and then combining them.

The pharmaceutical composition for treating or preventing sleep disorders in the present invention can be provided with compound A in combination with at least one active component selected from zolpidem, zopiclone, triazolam and brotizolam, for example, in the alternative forms prepared by the following procedures. (1) the above components are mixed optionally with a pharmaceutically acceptable excipient or the like by the known pharmaceutical technology to provide one dosage form, (2) the respective components are independently processed, optionally together with a pharmaceutically acceptable excipient or the like, to use in combination with independent dosage forms, at the same time or at staggered times, or (3) the respective components are independently processed, optionally together with a pharmaceutically acceptable excipient or the like, to provide independently prepared dosage forms as a set (kit). In the pharmaceutical composition of the present invention, in case that the respective components are independently processed to provide independently prepared dosage forms, they can be administered to one patient at the same time or at staggered times, and the numbers of dosing of the respective dosage forms may or may not be equal.

The pharmaceutical composition for treating or preventing sleep disorders in the present invention can be provided in one dosage form containing all of the active components or in dosage forms in which the respective active components or part of them are independently prepared. The amount of active components is from about 0.01 to about 100% by weight of the total weight of the composition. This composition can be administered to patients by the oral route, such as tablets, fine granules, capsules and granules, among others. Preferred are tablets, fine granules, and capsules.

The pharmaceutical compositions in the present invention can be formulated in any *per se* known manner or analogous methods thereof available with pharmaceutically acceptable carriers used in any *per se* known manner.

5 The said carriers include any ordinary organic and inorganic carrier substances that are usable as formulating medicines. For example, employable are excipients, lubricants, binders, disintegrators, etc. for formulating solid preparations; and solvents, solubilizers, suspending
10 agents, isotonizing agents, buffers, soothing agents, etc. for formulating liquid preparations. If desired, further employable are other additives such as ordinary preservatives, antioxidants, colorants, sweeteners, adsorbents, wetting agents, etc.

15 The excipients include, for example, lactose, white sugar, D-mannitol, starch, corn starch, crystalline cellulose, light silicic anhydride, etc.

 The lubricants include, for example, magnesium stearate, calcium stearate, talc, colloidal silica, etc.

20 The binders include, for example, crystalline cellulose, white sugar, D-mannitol, dextrin, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, polyvinyl pyrrolidone, starch, sucrose, gelatin, methyl cellulose, carboxymethyl cellulose sodium, etc.

25 The disintegrators include, for example, starch, carboxymethyl cellulose, carboxymethyl cellulose calcium, croscarmellose sodium, carboxymethyl starch sodium, L-hydroxypropyl cellulose, etc.

 The solvents include, for example, water for
30 injections, alcohol, propylene glycol, macrogol, sesame oil, corn oil, olive oil, etc.

 The solubilizers include, for example, polyethylene glycol, propylene glycol, D-mannitol, benzyl benzoate,

ethanol, trisaminomethane, cholesterol, triethanolamine, sodium carbonate, sodium citrate, etc.

The suspending agents include, for example, surfactants such as stearyl triethanolamine, sodium lauryl sulfate, lauryl aminopropionic acid, lecithin, benzalkonium chloride, benzethonium chloride, glycerin monostearate, etc.; hydrophilic polymers such as polyvinyl alcohol, polyvinyl pyrrolidone, carboxymethyl cellulose sodium, methyl cellulose, hydroxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, etc.

The isotonizing agents include, for example, glucose, D-sorbitol, sodium chloride, glycerin, D-mannitol, etc.

The buffers include, for example, liquid buffers of phosphates, acetates, carbonates, citrates, etc.

The soothing agents include, for example, benzyl alcohol, etc.

The preservatives include, for example, parahydroxybenzoates, chlorobutanol, benzyl alcohol, phenethyl alcohol, dehydroacetic acid, sorbic acid, etc.

The antioxidants include, for example, sulfites, ascorbic acid, etc.

The stabilizers for light include, for example, titanium oxide, etc.

The pharmaceutical composition containing compound A used in the present invention can be provided in various dosage forms, for example, as tablets (including sugar-coated tablets, film-coated tablets), powders, granules, capsules (including soft capsules), liquids, injections, suppositories, sustained release preparations, plasters and also as chewing gum, etc., in accordance with the per se known methods, for example, the methods disclosed in WO 97/32871 or analogous methods thereto.

The pharmaceutical composition which comprises at

least one components selected from zolpidem, zopiclone, triazolam and brotizolam can be prepared in the same manners used in the above pharmaceutical composition containing compound A.

5 The pharmaceutical composition for treating or preventing sleep disorders which comprises compound A in combination with at least one active component selected from zolpidem, zopiclone, triazolam and brotizolam can reduce the amount (dose) of active component(s) required
10 compared to the case with the monotherapy using any of the above-mentioned active components. Namely, in the present invention, it is preferred to use zolpidem, zopiclone, triazolam and brotizolam in a lower amount than the case with monotherapy using their active components for treating
15 or preventing sleep disorders. In the present invention, for example, a combination of active component(s) in the respective amount of which separately cannot produce beneficial effects exhibits an action for sleep and reduces problematic side effects (e.g. rebound insomnia, dysmnnesia, ataxia after sleep-awake and somnolence). In other words,
20 in the present invention, the amount of zolpidem, zopiclone, triazolam and/or brotizolam can be reduced to an amount which do not produce side effects and an effect for sleep can be produced with the lower amount.

25 Compound A does not produce side effects in a monotherapy dose.

 The pharmaceutical composition for treating or preventing sleep disorders which comprises compound A in combination with at least one active component selected
30 from zolpidem, zopiclone, triazolam and brotizolam is useful for treating and/or preventing, for example, sleep disorders [e.g., primary insomnia, sleep-awake rhythm disorders (e.g., work-shift syndrome, time-zone

syndrome(jet-lag), seasonal melancholia, genital disorder, neuroendocrine disorder, senile dementia, Alzheimer's disease, various disorders accompanied by aging, cerebrovascular disorders (e.g., cerebral hemorrhage, etc.), cranial injury, spinal injury, epilepsy, anxiety, depression, manic-depressive psychosis, schizophrenia, alcoholism, Parkinson's disease, hypertension, arteriosclerosis, arrhythmia, premenstrual tension syndrome, glaucoma, cancer, aids and diabetes in mammals (e.g., human, cat, dog, monkey, etc.). In addition, it is also effective for protection against aging, immunoregulation, and ovulatory regulation (e.g., contraception). Compound A is independently useful for treating and/or preventing, for example, sleep disorders[e.g., primary insomnia, sleep-awake rhythm disorders(e.g., work-shift syndrome, time-zone syndrome(jet-lag), seasonal melancholia, genital disorder, neuroendocrine disorder, senile dementia, Alzheimer's disease, various disorders accompanied by aging, cerebrovascular disorders (e.g., cerebral hemorrhage, etc.), cranial injury, spinal injury, epilepsy, anxiety, depression, manic-depressive psychosis, schizophrenia, alcoholism, Parkinson's disease, hypertension, arteriosclerosis, arrhythmia, premenstrual tension syndrome, glaucoma, cancer, aids and diabetes in mammals (e.g., human, cat, dog, monkey, etc.), in addition protection against aging, immunoregulation, and ovulatory regulation (e.g., contraception).

The pharmaceutical composition for treating or preventing sleep disorders in the present invention is of low toxicity and can be used safely for human with oral administration.

Though the dose of the pharmaceutical composition of

the present invention varies, depending on the subject to which the composition is administered, the administration route employed, the disorder of the subject, the kinds of active components used, etc., for example, as the
5 respective active components dose for adults (body weight about 60 kg) with sleep disorders, the following amount may be administered once or several times a day, at the same time or at an interval of 30 minutes or 3 hours.

10 The dose of compound A may be from about 0.05 to about 10 mg of body weight, preferably from about 0.1 to about 3 mg of body weight for one administration.

15 The dose of zolpidem may be from about 0.2 to about 10 mg of body weight, preferably from about 0.5 to about 5 mg of body weight for one administration.

15 The dose of zopiclone may be from about 0.2 to about 10 mg of body weight, preferably from about 0.5 to about 5 mg of body weight for one administration.

20 The dose of triazolam may be from about 0.01 to about 0.5 mg/kg of body weight or so, preferably from about 0.02 to about 0.3 mg/kg of body weight for one administration.

20 The dose of brotizolam may be from about 0.01 to about 1 mg of body weight or so, preferably from about 0.05 to about 0.3 mg of body weight for one administration.

25 In the pharmaceutical composition for treating or preventing sleep disorders in the present invention, the ratio in combination of compound A with at least one selected from zolpidem, zopiclone, triazolam and brotizolam (relative dosage) is 0.1 to 30 part by weight per 1 part by weight of compound A.

30 The pharmaceutical composition for treating or preventing sleep disorders in the present invention may be used with other active components (e.g., benzodiazepine-type medicines comprising benzodiazepine

compounds such as diazepam, alprazolam, estazolam, etc.; agents for regulating sleep rhythm comprising fatty acid derivatives such as butoctamide and its salt, etc.; sleep reducing substances comprising cis-9,10-octadecenamide, etc. Such other active components and the compound A and at least one active component selected from zolpidem, zopiclone, triazolam and brotizolam may be mixed by means of *per se* known methods to give pharmaceutical compositions (e.g., tablets, powders, granules, capsules including soft capsules, liquids, injections, suppositories, sustained release preparations, etc.); or they may be separately formulated into different preparations, which may be administered to one and the same subject either simultaneously or at different times.

Best mode for carrying out the invention

The invention will be described in more detail hereinafter, with reference to the following Reference Examples, Preparation Examples and Experimental Examples, which, however, are to concretely illustrate some embodiments of the invention and are not intended to restrict the scope of the invention. Various changes and modifications can be made within the range that does not deviate from the scope of the invention.

Examples

Reference Example 1

2,3-Dihydrobenzofuran-5-carbaldehyde

To a solution of 2, 3-dihydrobenzofuran (100.0g, 832 mmols) in N,N-dimethylformamide (134.0g, 1.83mols) was added dropwise phosphorus oxychloride (255.1g, 1.66mols), then the mixture was stirred at 80-90°C for 7.5 hours. The mixture was cooled to room temperature, poured into water

(1L), and stirred for 15 hours. The product was extracted with toluene (1.5L). The extract was washed with water (500mL) followed by saturated aqueous solution of sodium bicarbonate (500mL) and concentrated under reduced pressure to obtain 115.9g (yield : 94%) of the title compound.

Reference Example 2

Ethyl (E)-3-(2,3-dihydrobenzofuran-5-yl)-2-propenoate

To an ice-cooled suspension of sodium t-butoxide (90.4g, 941mmols) in toluene (1L) was added dropwise triethyl phosphonoacetate (211.0g, 941mmols) followed by 2, 3-dihydrobenzofuran-5-carbaldehyde (115.9g, 782mmols). The mixture was stirred for 1 hour and then acetic acid (12g, 200mmols) and water (604mL) was added. The separated organic layer was washed with water (525mL) followed by saturated aqueous solution of sodium bicarbonate (263mL) and concentrated under reduced pressure. Methanol (525mL) and water (525mL) was added to the residue and the mixture was stirred for 30 min. Crystals precipitated were collected by filtration to obtain 161.2g (yield : 94%) of the title compound.

Reference Example 3

Ethyl 3-(2,3-Dihydrobenzofuran-5-yl)propionate

To a solution of ethyl (E)-3-(2,3-dihydrobenzofuran-5-yl)-2-propenoate (160.0g, 733mmols) in acetic acid (960mL) was added 5% palladium on activated carbon (32.0g, 50% hydrous). The mixture was stirred at 50°C for 3.5 hours under hydrogen atmosphere (ambient pressure). The catalyst was filtered off and the filtrate containing 156.7g (yield : 97%) of the title compound was obtained which was provided to the next step.

Reference Example 4

3-(6,7-Dibromo-2,3-dihydrobenzofuran-5-yl)propionic acid

5 Sodium acetate (59.2g, 722mmols) was dissolved in a solution of ethyl 3-(2,3-dihydrobenzofuran-5-yl)propionate (156.7g, 711mmols) in acetic acid, which was obtained in Reference Example 3. To the solution was added dropwise bromine (708g, 4.43mols). The reaction mixture
10 was stirred at room temperature for 4 hours and then added to a precooled 15% aqueous solution of sodium sulfite (2527g) followed by refluxing with acetonitrile (480mL) for 2 hours. After cooling, crystals were collected by filtration and washed with water to obtain 179.3g (yield:
15 72%) of the title compound.

Reference Example 5

4,5-Dibromo-1,2,6,7-tetrahydro-8H-indeno[5,4-b]furan-8-one

20 A mixture of 3-(6,7-dibromo-2,3-dihydrobenzofuran-5-yl)propionic acid (10.0g, 28.6mmols), dichloromethane (35mL), thionyl chloride (5.11g, 40.8mmols) and N,N-dimethylformamide (30mg) was heated to reflux for 1 hour. After cooling, aluminum chloride (4.66g,
25 43.3mmols) was added to the reaction mixture blow 0°C and then the mixture was stirred for 30 min. The reaction mixture was poured into precooled methanol (200mL), then stirred for 30 min. Crystals precipitated were collected by filtration, washed with water (500mL) followed by
30 methanol (500mL) to obtain 7.9g (yield : 89%) of the title compound.

Reference Example 6

1,2,6,7-Tetrahydro-8H-indeno[5,4-b]furan-8-one

To a suspension of 4,5-dibromo-1,2,6,7-tetrahydro-8H-indeno[5,4-b]furan-8-one (18.4 g, 55.4 mmols) in methanol (400mL) was added 10% Palladium on activated carbon (2.0 g, 50% hydrous) followed by sodium acetate (12.6 g, 154mmols). The mixture was stirred at 40°C for 1.5 hours under hydrogen atmosphere (4kgf/cm²). The catalyst was filtered off and the filtrate was concentrated under reduced pressure. Crystals were collected by filtration, washed with water and recrystallized successively with methanol : water = 5 : 1 to obtain 8.0 g (yield : 83%) of the title compound.

Reference Example 7

(E)-(1,6,7,8-Tetrahydro-2H-indeno[5,4-b]furan-8-ylidene)acetonitrile

To a solution of 1,2,6,7-tetrahydro-8H-indeno[5,4-b]furan-8-one (250.0g, 1.44mols) and diethyl (cyanomethyl) phosphonate (304.8g, 1.72mols) in toluene(6.25L) was added dropwise 28% sodium methoxide in methanol (332.8g, 1.72mols). After stirring for 2 hours under the same temperature, water (2.5L) was added to the reaction mixture to separate organic layer which was washed with water (1L) and concentrated under reduced pressure. Crystals were collected by filtration to obtain 250.4g (yield : 88%) of the title compound.

Reference Example 8

(E)-2-(1,6,7,8-Tetrahydro-2H-indeno[5,4-b]furan-8-indene)ethylamine hydrochloride

To a solution of (E)-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-ylidene)acetonitrile (30.0g, 152mmols) in toluene (500mL) were added methanol (100mL),

14.4% aqueous solution of sodium hydroxide (10.5g) and Raney cobalt (44g). The mixture was stirred at 35°C for 5.5 hours under hydrogen atmosphere (2kgf/cm²). After the catalyst was filtered off, water (160mL) and 1N-HCl (150mL) were added to the filtrate, then the mixture was stirred at 40°C for 30 min. Aqueous layer was separated and saturated aqueous solution of sodium chloride (320mL) was added. The precipitated crystals were collected by filtration to obtain 30.0g (yield: 83%) of the title compound.

Reference Example 9

(S)-2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl) ethylamine hydrochloride

A Hastelloy autoclave (200 mL) was charged with (E)-2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-ylidene) ethylamine (1.00 g, 5.00 mmol.), Ru₂Cl₄[(R)-BINAP]₂NEt₃ (21.0 mg) and methanol (10 mL) under nitrogen atmosphere. Into the vessel, hydrogen gas was introduced up to 100 atmospheric pressure. The mixture was stirred for 20 hours at 50°C. The reaction system was depressurized to normal, followed by determination of the conversion and the optical purity of the product, (S)-2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl) ethylamine), by means of high performance liquid chromatography. The conversion was 100% and the optical purity was 88.8%e.e.

Toluene (10 mL) was added to the residue (1.02 g) obtained by concentration under reduced pressure. The mixture was cooled on an ice-bath, to which was added, while stirring, 2% hydrochloric acid (10 mL). The reaction mixture was stirred for 30 minutes, which was concentrated under reduced pressure to leave the residue (1.21 g). The concentrate was dissolved in methanol (5 mL), to which was added acetone (10 mL). The mixture was cooled to 0°C, which

was then subjected to filtration to collect the title compound (0.64 g). Further, the filtrate was concentrated under reduced pressure. The concentrate (0.34 g) was recrystallized from a mixture of methanol (1.5 mL) and acetone (3.0 mL) to give the title compound (0.17 g, total yield 0.81 g, yield 68%). This hydrochloride was processed with a 5% aqueous solution of sodium hydroxide to give (S)-2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethylamine. The optical purity of the product was determined by means of high performance liquid chromatography, which was 100 %e.e.

Reference Example 10

(S)-N-[2-(1,6,7,8-Tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide (compound A)

To a suspension of (S)-2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethylamine hydrochloride (100.0g, 417mmol) in tetrahydrofuran (250mL) at 15°C was added dropwise 7.1% aqueous solution of sodium hydroxide (538mL). Propionyl chloride (44.4g, 480mmol) was added dropwise to the reaction mixture. Stirring was continued at room temperature for 30 min. Water (800mL) was added and crystals precipitated were collected by filtration followed by recrystallization from ethanol : water = 1: 2 to obtain 99.5g (yield : 92%) of the title compound.

Preparation Example 1

(1)compound A	10.0g
(2)lactose	60.0g
(3)corn starch	35.0g
(4)gelatin	3.0g
(5)magnesium stearate	2.0g

Compound A (10.0 g), lactose (60.0 g) and corn starch (35.0 g) were mixed and the mixture was granulated with 10%(w/v) aqueous solution dissolving gelatin (gelatin 3.0

g) by using a screen with 1mm mesh, and was dried at 40° C and screened. Thus-obtained granules were mixed with magnesium stearate (2.0g) and compressed to give uncoated-tablets. The uncoated-tablets were sugar-coated with a fluid containing cane sugar, titanium dioxide, talc and arabic gum and polished with beeswax to give 1000 coated tablets.

Preparation Example 2

10	(1) compound A	10.0g
	(2) lactose	70.0g
	(3) corn starch	50.0g
	(4) soluble starch	7.0g
	(5) magnesium stearate	3.0g

15 Compound A (10.0g) and magnesium stearate (3.0g) were granulated with 70mL of aqueous solution dissolving soluble starch (7.0g of soluble starch). The granules were dried and mixed with lactose (70.0g) and corn starch (50.0g). The mixtures were compressed to give 1000 tablets.

20

Preparation Example 3

	(1) compound A	1.0g
	(2) lactose	60.0g
	(3) corn starch	35.0g
25	(4) soluble starch	3.0g
	(5) magnesium stearate	2.0g

30 Compound A (1.0g), lactose (60.0g) and corn starch (35.0g) were mixed and the mixture was granulated with 30mL of 10% (w/v) aqueous solution dissolving gelatin (gelatin 3.0g) by using a screen with 1mm mesh, and was dried at 40° C and screened. The thus-obtained granules were mixed with magnesium stearate (2.0g) and compressed to give uncoated-tablets. The uncoated-tablets were sugar-coated

with a fluid containing cane sugar, titanium dioxide, talc and arabic gum and polished with beeswax to give 1000 coated tablets.

5 Experimental Example

Methods

Six female crab-eating macaques (*Macaca fascicularis*), weighing 2.8-4.2 kg, housed individually in a room maintained at $24\pm1^{\circ}\text{C}$ with a 12-h light/dark cycle (light on 6:00). Under sodium pentobarbital anesthesia, stainless steel screw and bipolar electrodes for electroencephalogram (EEG), electromyogram (EMG) and electro-oculogram (EOG) were implanted. After recovery from surgery, the monkeys were well habituated to the recording chamber (60×60×80 cm) located in a sound-proof and electrically shielded room. Compound A (0.003 mg/kg) and/or triazolam (0.03 mg/kg) were given orally 17:50-17:55. Compound A and triazoilam were suspended in 0.5% methylcellulose solution. The control monkey was given 0.5% MC. The behaviors of subjects were observed using a video camera with infrared light sensitivity. The EEG, EMG and EOG were recorded on a MO disk with an electroencephalograph (EE5518, NEC Medical Systems, Tokyo, Japan). All recordings were carried out from 18:00 until 6:00. The EEG power spectral analysis was also performed continuously by means of a fast Fourier transform (FFT) system equipped with a personal computer. Based on these EEG, EMG and EOG data and on behavior, visually judged in each 20-sec epoch, we classified the sleep-wake stages according to Rechtshaffen and Kales (1968) essentially (i.e. stage W, stage 1+2, stage 3, stage 4 and stage rapid eye movement (REM)). Latencies of each sleep stage (the time until the first appearance of each sleep stage) were

determined from 18:00. The occurrence of each sleep stage at nighttime and other sleep parameters were also determined.

5 Results

Treatment with compound A (0.003 mg/kg, p.o.) had no significant effects on the latency of any sleep stages. Triazolam (0.03 mg/kg, p.o.) alone also produced no significant effects on the sleep latencies. Treatment
10 with triazolam (0.03 mg/kg) did not affect general behavior and it did not cause ataxia and sedation as such were seen when high doses of triazolam are given. The effects of co-administration of compound A and triazolam on the sleep latency are shown in Fig. 1. Co-administration of Compound
15 A and triazolam shortened the latencies of deep slow wave sleep, stage 3 and stage 4, and it significantly shortend the latency of the stage 4 sleep. The co-administration also had no significant effects on general behavior of monkeys.

20 It is clear that compound A in combination with triazolam has an excellent effect on the sleep disorders without the side effects.

(Rechtschaffen; A. and Kales, A.A.: A Manual of Standardized Terminology, Techniques and Scoring System
25 for Sleep Stages of Human Subjects. Bethesda, M.D., US Department of Health, Education and Welfare, 1968.)

Industrial Applicability

The pharmaceutical composition for treating or
30 preventing sleep disorders which comprises (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide (compound A) in combination with at least one active component selected from zolpidem,

zopiclone, triazolam and brotizolam in one dosage form or independent dosage forms and the method for treating or preventing which comprises administering the composition to a mammal is useful for treating and/or preventing, for example, sleep disorders [e.g., primary insomnia, sleep-awake rhythm disorders (e.g., work-shift syndrome, time-zone syndrome(jet-lag), seasonal melancholia, genital disorder, neuroendocrine disorder, senile dementia, Alzheimer's disease, various disorders accompanied by aging, cerebrovascular disorders (e.g., cerebral hemorrhage, etc.), cranial injury, spinal injury, epilepsy, anxiety, depression, manic-depressive psychosis, schizophrenia, alcoholism, Parkinson's disease, hypertension, arteriosclerosis, arrhythmia, premenstrual tension syndrome, glaucoma, cancer, aids and diabetes in mammals (e.g., human, cat, dog, monkey, etc.). In addition, it is also effective for protection against aging, immunoregulation, and ovulatory regulation (e.g., contraception). Compound A is independently useful for treating and/or preventing, for example, sleep disorders[e.g., primary insomnia, sleep-awake rhythm disorders(e.g., work-shift syndrome, time-zone syndrome(jet-lag), seasonal melancholia, genital disorder, neuroendocrine disorder, senile dementia, Alzheimer's disease, various disorders accompanied by aging, cerebrovascular disorders (e.g., cerebral hemorrhage, etc.), cranial injury, spinal injury, epilepsy, anxiety, depression, manic-depressive psychosis, schiaophrenia, alcoholism, Parkinson's disease, hypertension, arteriosclerosis, arrhythmia, premenstrual tension syndrome, glaucoma, cancer, aids and diabetes in mammals (e.g., human, cat, dog, monkey, etc.), in addition protection against aging, immunoregulation, and ovulatory regulation (e.g., contraception).

Claims

1. A pharmaceutical composition for treating or preventing sleep disorders which comprises (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide in combination with at least one active component selected from zolpidem, zopiclone, triazolam and brotizolam.
2. A pharmaceutical composition for treating or preventing sleep disorders which comprises (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide in combination with at least one active component selected from zolpidem, zopiclone and triazolam.
3. Use of (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide in combination with at least one active component selected from zolpidem, zopiclone, triazolam and brotizolam for treating or preventing sleep disorders.
4. Use of combination of (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide with at least one active component selected from zolpidem, zopiclone, triazolam and brotizolam for the production of a pharmaceutical composition for treating or preventing sleep disorders.
5. A method for treating or preventing sleep disorders in a mammal in need thereof, which comprises administering to such mammal an effective amount of (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide in combination with at least one active component selected from zolpidem, zopiclone, triazolam and brotizolam.
6. A method for reducing the amount of active component(s)

administered to a mammal for treating or preventing sleep disorders, which comprises administering to such mammal an effective amount of (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-

5 yl)ethyl]propionamide in combination with at least one active component selected from zolpidem, zopiclone, triazolam and brotizolam.

7. A method for reducing the side effects of active component(s) administered to a mammal for treating or preventing sleep disorders, which comprises administering to such mammal an effective amount of (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide in combination with at least one active component selected from zolpidem, zopiclone, triazolam and brotizolam.

10

15

1/1




Fig.1